Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa

While Gilead was crossing the last t’s and dotting the last i’s on their $21 billion deal to buy Immunomedics and their ADC for triple negative breast cancer, Merck was doing the same for a two-pronged, $4.5 billion pact with Seattle Genetics covering another ADC with the same disease target…

Click to view original post